To study the tumorigenic effect of NELF in vivo, we generated CRISPR-mediated genetic knockouts (KOs) of NELF-A and NELF-E in the highly aggressive SUM159 breast cancer cell line (triple-negative subtype). The gene discussed is NELFE; the disease is breast carcinoma.